Literature DB >> 15983801

Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task.

Garry D Honey1, Rebekah A E Honey, Sam R Sharar, Danielle C Turner, Edith Pomarol-Clotet, Dharshan Kumaran, Jon S Simons, Xiangen Hu, Michael D Rugg, Edward T Bullmore, Paul C Fletcher.   

Abstract

RATIONALE: The precise nature of the impact of the N-methyl-D-aspartate antagonist, ketamine, upon human episodic memory, has yet to be elucidated fully.
OBJECTIVES: This study sought to assess the effects of ketamine on the sub-processes facilitating memory encoding and retrieval.
METHODS: We evaluated the effects of the drug on a series of memory performance measures depending upon whether it was administered at the encoding or retrieval stage and on the nature of the encoding task used. Twelve healthy volunteers participated in a double-blind, placebo-controlled, randomized, within-subjects study. Intravenous infusions of placebo, 50 ng/ml ketamine or 100 ng/ml ketamine were administered. We investigated the effects of ketamine on three key aspects of episodic memory: encoding vs retrieval processes, source memory, and depth of processing. Data were analysed using both multinomial modelling and standard measures of item discrimination and response bias.
RESULTS: Deleterious effects of ketamine on episodic memory were primarily attributable to its effects on encoding, rather than retrieval processes. Recognition memory was impaired for items encoded at an intermediate level of processing, but preserved for shallowly and deeply encoded items. Increased source guessing bias was also observed when encoding took place under ketamine.
CONCLUSIONS: The effects of ketamine upon episodic memory seem, therefore, to predominate at encoding. Furthermore, our results are also consistent with a specific impairment of encoding processes that result in subsequent recollective, as opposed to familiarity-based, retrieval. The observed effects are compatible with memory deficits seen in schizophrenia and thus provide some support for the ketamine model of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983801     DOI: 10.1007/s00213-005-0001-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  44 in total

1.  A multinomial modeling analysis of memory deficits in Alzheimer's disease and vascular dementia.

Authors:  W H Batchelder; J Chosak-Reiter; W R Shankle; M B Dick
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  1997-09       Impact factor: 4.077

2.  Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers.

Authors:  L A Hetem; J M Danion; P Diemunsch; C Brandt
Journal:  Psychopharmacology (Berl)       Date:  2000-10       Impact factor: 4.530

3.  Recall and recognition in chronic nondemented schizophrenics: use of matched tasks.

Authors:  A Calev
Journal:  J Abnorm Psychol       Date:  1984-05

4.  Clinical and neurocognitive aspects of source monitoring errors in schizophrenia.

Authors:  S Vinogradov; J Willis-Shore; J H Poole; E Marten; B A Ober; G K Shenaut
Journal:  Am J Psychiatry       Date:  1997-11       Impact factor: 18.112

5.  NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

Authors:  A K Malhotra; D A Pinals; H Weingartner; K Sirocco; C D Missar; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1996-05       Impact factor: 7.853

6.  Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay.

Authors:  E F Domino; E K Zsigmond; L E Domino; K E Domino; S P Kothary; S E Domino
Journal:  Anesth Analg       Date:  1982-02       Impact factor: 5.108

7.  Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

Authors:  Rebekah A E Honey; Danielle C Turner; Garry D Honey; Sam R Sharar; D Kumaran; E Pomarol-Clotet; P McKenna; B J Sahakian; T W Robbins; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

8.  Amnesic syndrome in schizophrenia.

Authors:  P J McKenna; D Tamlyn; C E Lund; A M Mortimer; S Hammond; A D Baddeley
Journal:  Psychol Med       Date:  1990-11       Impact factor: 7.723

9.  Evidence for distinct verbal memory pathologies in severely and mildly disturbed schizophrenics.

Authors:  A Calev; P H Venables; A F Monk
Journal:  Schizophr Bull       Date:  1983       Impact factor: 9.306

10.  Forms of memory failure in schizophrenia.

Authors:  J M Gold; C Randolph; C J Carpenter; T E Goldberg; D R Weinberger
Journal:  J Abnorm Psychol       Date:  1992-08
View more
  21 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  On the measurement of the effects of alcohol and illicit substances on inhibition of return.

Authors:  Janine V Olthuis; Raymond M Klein
Journal:  Psychopharmacology (Berl)       Date:  2012-05-09       Impact factor: 4.530

3.  KETAMINE AS A POSSIBLE MODERATOR OF HYPNOTIZABILITY: A FEASIBILITY STUDY.

Authors:  David R Patterson; Christine Hoffer; Mark P Jensen; Shelley A Wiechman; Sam R Sharar
Journal:  Int J Clin Exp Hypn       Date:  2018 Jul-Sep

4.  Brain activation by short-term nicotine exposure in anesthetized wild-type and beta2-nicotinic receptors knockout mice: a BOLD fMRI study.

Authors:  S V Suarez; A Amadon; E Giacomini; A Wiklund; J-P Changeux; D Le Bihan; S Granon
Journal:  Psychopharmacology (Berl)       Date:  2008-09-26       Impact factor: 4.530

5.  High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Authors:  W Louis Cleveland; Robert L DeLaPaz; Rashid A Fawwaz; Roger S Challop
Journal:  Neural Plast       Date:  2010-02-18       Impact factor: 3.599

6.  Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia.

Authors:  Jinsong Tang; Hannah L Morgan; Yanhui Liao; Philip R Corlett; Dong Wang; Hong Li; Yanqing Tang; Jindong Chen; Tieqiao Liu; Wei Hao; Paul C Fletcher; Xiaogang Chen
Journal:  Psychopharmacology (Berl)       Date:  2014-11-19       Impact factor: 4.530

7.  Greater vulnerability to the amnestic effects of ketamine in males.

Authors:  Celia J A Morgan; Edward B Perry; Hyung-Sang Cho; John H Krystal; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

Review 8.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 9.  Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Authors:  Weili Zhu; Zengbo Ding; Yinan Zhang; Jie Shi; Kenji Hashimoto; Lin Lu
Journal:  Neurosci Bull       Date:  2016-11-22       Impact factor: 5.203

Review 10.  Multistage drug effects of ketamine in the treatment of major depression.

Authors:  Martin Walter; Shijia Li; Liliana Ramona Demenescu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-13       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.